Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
289 hedge funds and large institutions have $8.16B invested in Karuna Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 72 funds opening new positions, 92 increasing their positions, 90 reducing their positions, and 29 closing their positions.
148% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 29
87% more call options, than puts
Call options by funds: $207M | Put options by funds: $111M
17% more funds holding
Funds holding: 246 → 289 (+43)
16% more capital invested
Capital invested by funds: $7.02B → $8.16B (+$1.14B)
2% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 90
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$129M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$60.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$53.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.5M |
| 5 |
Millennium Management
New York
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$130M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$119M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$111M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$84M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$51.9M |
KRTX Hedge Fund Activity: Q2 2023 in Review
289 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q2 2023, worth a combined $8.16B — up 16% from $7.02B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new KRTX positions and 29 closed out — a net gain of 43 holders — while 92 added to existing stakes and 90 trimmed.
The largest buyer was Capital International Investors, adding an estimated $129M. The largest seller was BlackRock, cutting an estimated $130M.
- 289 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q2 2023, up from 246 in Q1 2023.
- Funds reported $8.16B of Karuna Therapeutics, Inc. Common Stock stock for Q2 2023, up 16% quarter-over-quarter.
- 72 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q2 2023 and 29 closed out, a net change of +43 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q2 2023 was Capital International Investors, an estimated $129M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q2 2023 was BlackRock, an estimated $130M sold.
Based on aggregated 13F filings for Q2 2023.